Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $3.0 million.

  • UroGen Pharma's Share-based Compensation fell 1324.16% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 229.52%. This contributed to the annual value of $13.1 million for FY2024, which is 4028.25% up from last year.
  • UroGen Pharma's Share-based Compensation amounted to $3.0 million in Q3 2025, which was down 1324.16% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Share-based Compensation registered a high of $6.2 million during Q1 2021, and its lowest value of $2.2 million during Q2 2023.
  • Its 5-year average for Share-based Compensation is $3.4 million, with a median of $2.9 million in 2022.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 5579.62% in 2022, then skyrocketed by 6021.6% in 2024.
  • Over the past 5 years, UroGen Pharma's Share-based Compensation (Quarter) stood at $5.4 million in 2021, then tumbled by 55.8% to $2.4 million in 2022, then increased by 10.3% to $2.6 million in 2023, then grew by 26.45% to $3.3 million in 2024, then fell by 8.36% to $3.0 million in 2025.
  • Its Share-based Compensation was $3.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.1 million in Q1 2025.